Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT02763319
- Locations
- 🇬🇧
MorphoSys Research Site, Southend on Sea, United Kingdom
🇬🇧Morphosys Research Site, Birmingham, United Kingdom
🇨🇿Morphosys Research site, Olomouc, Czechia
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT02760485
- Locations
- 🇺🇸
LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles, California, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 706
- Registration Number
- NCT02752074
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02718300
- Locations
- 🇺🇸
California Cancer Associates For Research and Excellence, Fresno, California, United States
🇺🇸Baylor Scott and White Research Institute, Dallas, Texas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT02712905
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Kansas Center for Research, Inc., Kansas City, Kansas, United States
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT02711137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 159
- Registration Number
- NCT02646748
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Georgetown University Medical Center Lombardi CCC, Washington, District of Columbia, United States
🇺🇸The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision), Bethesda, Maryland, United States
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 31
- Registration Number
- NCT02614612
Study of INCB053914 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 97
- Registration Number
- NCT02587598
- Locations
- 🇺🇸
Texas Oncology, Tyler, Texas, United States
🇺🇸Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UC Davis comprehensive Cancer Center, Sacramento, California, United States